CAD Event Cholesterol Test

©2013 Truven Health Analytics Inc. Proprietary and confidential.

MEASURE DESCRIPTION:

CAD Event Cholesterol Test indicates whether a patient, aged 18 to 75 years, who either had a cardiovascular event during the year prior to the measurement year, or had a diagnosis of ischemic vascular disease (IVD) during both the measurement year and the year prior, had at least one LDL cholesterol screening test done.

This measure is based on the HEDIS measure Cholesterol Management for Patients With Cardiovascular Conditions (CMC).

PROPRIETARY STATUS:

This measure is owned by NCQA [NQF-Endorsed ™].

CRITERIA REVISION:

This measure is based on the HEDIS® 2013 Technical Specifications for Physician Measurement criteria.

CRITERIA REVIEW DATE: 04/05/2013

MEASURE TYPE:

MEASURE PACKAGE: Advantage Nationally Endorsed

MINIMUM DATA REQUIREMENTS (months): 24

MEASURE DETAILS:

DENOMINATOR:

Identifies the unique count of patients, aged 18 to 75 years at the end of the measurement year, who either had a cardiovascular event during the year prior to the measurement year, or had a diagnosis of ischemic vascular disease both during the measurement year and the year prior.

Discharged alive from an acute inpatient facility with a diagnosis of acute myocardial infarction (AMI) or a coronary artery bypass graft (CABG) procedure performed, based on *facility* claims (during the year prior to the measurement year up to 2 months before the beginning of the measurement year)

Place of Service Code Medstat = 21, 25, 51, 55

And

Room and Board Flag Code = 1

And

Discharge Status Code UB <> 20

And

(ICD-9 Diagnosis Code = 410.x1

Or

ICD-9 Procedure Code = 36.1*, 36.2

Or

CPT Procedure Code = 33510-33514, 33516-33519, 33521-33523, 33533-33536

Or

HCPCS Procedure Code = S2205-S2209)

OR	
Diagnosis of AMI or a CABG procedure performed on an inpatient basis, based on <i>professional</i> claims (during the year prior to the measurement year up to 2 months before the beginning of the measurement year)	Place of Service Code Medstat = 21, 25, 51, 55
	And
	ICD-9 Diagnosis Code = 410.x1
	And
	(CPT Procedure Code = 33510-33514, 33516-33519, 33521-33523, 33533-33536
	Or
	HCPCS Procedure Code = S2205-S2209)
OR	
A percutaneous coronary intervention (PCI) procedure performed in any setting (during the year prior to the measurement year up to 2 months before the beginning of the measurement year)	ICD-9 Procedure Code = 00.66, 36.01, 36.02, 36.05-36.07
	Or
	CPT Procedure Code = 92980, 92982, 92995
	Or
	HCPCS Procedure Code = G0290
OR	
At least one outpatient or acute inpatient visit with a diagnosis of ischemic vascular disease (IVD) (in both the measurement year and the year prior)	ICD-9 Diagnosis Code = 411*, 413*, 414.0*, 414.2, 414.8, 414.9, 429.2, 433.00-434.91, 440.1, 440.2*, 440.4, 444*, 445*
	And
	(CPT Procedure Code = 99201-99220, 99221-99233, 99238, 99239, 99241-99255, 99261-99263, 99291, 99341-99350, 99384-99387, 99394-99397, 99401-99404, 99411, 99412, 99420, 99429, 999455, 99456
	Or
	(Revenue Code UB = 010*, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016*, 0200-0219, 051*, 0520-0523, 0526-0529, 0570-0599, 072*, 0982, 0983, 0987
	And
	Place of Service Code Medstat = 4-12, 15-26, 49-53, 55, 57, 61-72, 95, 99))
AND	
Age in Years (as of the end of the measurement year)	Age in Years = 18-75

EXCLUSIONS:

None.

NUMERATOR:

Identifies patients, aged 18 to 75 years, who either had a cardiovascular event during the year prior to the measurement year, or had a diagnosis of IVD during both the measurement year and the year prior, and had at least one LDL cholesterol screening test done.

At least one LDL-C test (during the measurement year)	(CPT Procedure Code = 80061, 83700, 83701, 83704, 83715, 83716, 83721	
OR		
Performance measurement code indicating LDL-C test performed (during the measurement year)	CPT Procedure Code = 3048F, 3049F, 3050F)	

CONTINUOUS ENROLLMENT:

Continuously enrolled with medical coverage during the measurement year and the year prior to the measurement year, equating to 24 months out of 24 months.

MEASURE BACKGROUND:

Coronary artery disease (CAD) remains a major health problem in the United States. About 13 million Americans have CAD, and includes patients with angina, patients with prior heart attacks or coronary artery bypass surgery, or other procedures. According to the Centers for Disease Control and Prevention (CDC), heart disease was expected to cost the United States \$444 billion in 2011, including the cost of health care services, medications, and lost productivity. The disease accounts for about 20 percent of the deaths in the U.S. Cardiovascular disease affects both men and women of all racial and ethnic groups.

Mortality rates for cardiovascular disease (CVD) and CAD in men and women and in blacks and whites have fallen in most countries by 24 to 28 percent since 1975. Much of this reduction is due to improvement in medical therapies for CVD; the rest is due to risk-factor reduction, particularly a decline in smoking and treatment of hypertension. Patients with established CAD have a high risk of subsequent cardiovascular events, including myocardial infarction (MI), stroke, and death from CVD. There are many different aspects to managing patients with CAD, including beta blockade, cholesterol management, and antiplatelet agents. In accordance with current guidelines, patients with CAD should have their cholesterol checked, and treatment with a statin drug is generally recommended. Current recommendations indicate that LDL-C should be less than 100 mg/dL for most patients.

AMA PCPI Notice of Use. Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

The Measures are provided as is without warranty of any kind. ©2007 American Medical Association. All Rights Reserved.

CPT® copyright 2012 American Medical Association. All rights reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Applicable FARS/DFARS restrictions apply to government use. CPT is a registered trademark of the American Medical Association.

The LOINC® codes, LOINC® table (regardless of format), LOINC® Release Notes, LOINC® Changes File, and LOINC® Users Guide are copyright© 1995-2012, Regenstrief Institute, Inc., and the Logical Observation Identifiers Names and Codes (LOINC) Committee. All rights reserved.

NCQA Notice of Use. Broad public use and dissemination of these measures is encouraged and the measure developers have agreed with NQF that noncommercial uses do not require the consent of the measure developer. Use by health care providers in connection with their own practices is not commercial use. Commercial use of a measure does require the prior written consent of the measure developer. As used herein, a • commercial use• refers to any sale, license, or distribution of a measure for commercial gain, or incorporation of a measure into any product or service that is sold, licensed, or distributed for commercial gain (even if there is no actual charge for inclusion of the measure).

These performance measures were developed and are owned by the National Committee for Quality Assurance (• NCQA•). These performance measures are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures. NCQA holds a copyright in this measure and can rescind or alter this measure at any time. Users of the measure shall not have the right to alter, enhance, or otherwise modify the measure and shall not disassemble, recompile, or reverse engineer the source code or object code relating to the measure. Anyone desiring to use or reproduce the measure without modification for a noncommercial purpose may do so without obtaining any approval from NCQA. All commercial uses must be approved by NCQA and are subject to a license at the discretion of NCQA.

© 2009-2012 National Committee for Quality Assurance. All rights reserved.

RED BOOK™ is a trademark of Truven Health Analytics Inc.